Doximity Inc. logo

Doximity Inc. (DOCS)

Market Closed
3 Jul, 20:00
NYSE NYSE
$
61. 69
+2.38
+4.01%
$
11.47B Market Cap
51.81 P/E Ratio
0% Div Yield
1,058,400 Volume
0.86 Eps
$ 59.31
Previous Close
Day Range
59.33 61.7
Year Range
25 85.21
Want to track DOCS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 32 days
Doximity Crushes The Rule Of 40 - Try Rule Of 58

Doximity Crushes The Rule Of 40 - Try Rule Of 58

I have a price target of $85 for Doximity by summer 2026. There is lots to be bullish about. Doximity's fundamentals are strong: zero debt, a large cash cushion, and robust free cash flow generation support my bullish outlook. Despite unimpressive 11% revenue growth guidance, DOCS surpasses the Rule of 40 with a Rule of 58, justifying a premium valuation.

Seekingalpha | 2 days ago
Doximity (DOCS) Laps the Stock Market: Here's Why

Doximity (DOCS) Laps the Stock Market: Here's Why

Doximity (DOCS) concluded the recent trading session at $61.09, signifying a +1.13% move from its prior day's close.

Zacks | 1 week ago
Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot?

Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot?

DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots.

Zacks | 1 week ago
Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?

Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?

DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.

Zacks | 2 weeks ago
DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?

DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?

DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge.

Zacks | 2 weeks ago
Doximity: A Unique, Debt-Free Healthcare-Tech Platform, Initiate With 'Buy'

Doximity: A Unique, Debt-Free Healthcare-Tech Platform, Initiate With 'Buy'

I rate Doximity a 'Buy' with a $62 fair value, citing its dominant network among U.S. healthcare professionals and robust growth trajectory. Doximity's strong pharma marketing business, workflow solutions, and AI-driven hiring tools underpin its competitive advantage and long-term expansion potential. The company's debt-free balance sheet, high free cash flow, and substantial share repurchases support its financial health and margin expansion outlook.

Seekingalpha | 2 weeks ago
DOCS Boosts Client Retention via Workflow Integration and AI Tools

DOCS Boosts Client Retention via Workflow Integration and AI Tools

Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.

Zacks | 3 weeks ago
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm

NEW YORK , June 9, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Doximity caused the company to misrepresent or fail to disclose material information concerning the Company's business and operations.

Prnewswire | 3 weeks ago
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.

Globenewswire | 4 weeks ago
Doximity Declines 4.4% in a Month: How to Play the Stock Now?

Doximity Declines 4.4% in a Month: How to Play the Stock Now?

Over the past month, Doximity's DOCS shares have lost approximately 4.4% despite the company reporting solid fourth-quarter fiscal 2025 results with $138.3 million in revenues and a 50% adjusted EBITDA margin. For fiscal 2025, revenues totaled $570.4 million, up 20% year over year, with adjusted EBITDA rising 36% to $313.8 million and margin expanding to 55%.

Zacks | 4 weeks ago
Dr Martens surges 23% as investors lace up for recovery story

Dr Martens surges 23% as investors lace up for recovery story

Shares in Dr Martens PLC (LSE:DOCS) jumped 23% on Thursday after the bootmaker delivered a better-than-expected full-year update and signalled a shift towards stabilisation and future growth, giving investors reason to believe the worst may be behind it. The British brand, known for its chunky leather boots, reported adjusted pre-tax profits of £34.1 million for the year to March, around £2 million ahead of consensus and squarely in line with Peel Hunt's forecast.

Proactiveinvestors | 4 weeks ago
Dr Martens marketing 'reset' saw annual revenue and profit retreat, eyes return to growth this year

Dr Martens marketing 'reset' saw annual revenue and profit retreat, eyes return to growth this year

Dr Martens PLC (LSE:DOCS) reported a 10% drop in group revenue to £787.6 million for the year ended 30 March 2025, amidst a marketing 'reset'. Adjusted profit before tax fell to £34.1 million from £97.2 million, the boot brand said in the results statement.

Proactiveinvestors | 1 month ago
Loading...
Load More